Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

BAP1 inhibits glycolytic process. 2 / 2

| 2

➶

reach

"XREF_FIG shows that BAP1 +/- fibroblasts transduced with AdBAP1 had reduced glycolysis and glycolytic capacity; in contrast, AdC91S was ineffective at reducing glycolysis (rate of glycolysis in BAP1 +/- transduced with : AdGFP 24.94 +/-1.77 mpH and min, AdBAP1 6.92 +/-0.24 mpH and min, AdBAP1 (C91S) 20.33 +/-2.92 mpH and min; glycolytic capacity : AdGFP 30.33 +/-1.71 mpH and min, AdBAP1 11.50 +/-0.43 mpH and min, AdC91S 25.08 +/-3.25 mpH and min)."

28665402

➶

reach

"Additionally, reduced levels of BAP1 induce aerobic glycolysis, which favors tumor growth (64)."

35098108

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...